申请人:NAT INST OF BIOLOG SCIENCES BEIJING
公开号:WO2015158214A1
公开(公告)日:2015-10-22
The invention provides novel compounds and compositions comprising a 5-HT2B antagonist of formula I and related methods for treating a person having a disorder characterized by undesirable 5-HT2B receptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.
这项发明提供了一种新型化合物和组合物,包括式I的5-HT2B拮抗剂,以及用于治疗患有不良5-HT2B受体信号特征性紊乱的人的相关方法,如偏头痛、肠易激综合征(IBS)、肺动脉高压(PAH)、纤维化、肝细胞癌、小肠神经内分泌肿瘤、心血管疾病和胃肠道(GI)疾病。